X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
lenalidomide (3682) 3682
humans (2951) 2951
hematology (2135) 2135
oncology (1989) 1989
multiple myeloma (1969) 1969
bortezomib (1381) 1381
male (1337) 1337
female (1316) 1316
multiple myeloma - drug therapy (1226) 1226
aged (1217) 1217
thalidomide - analogs & derivatives (1193) 1193
middle aged (1151) 1151
thalidomide (1139) 1139
dexamethasone (1001) 1001
therapy (829) 829
treatment outcome (819) 819
antineoplastic combined chemotherapy protocols - therapeutic use (787) 787
adult (769) 769
stem-cell transplantation (739) 739
survival (699) 699
thalidomide - therapeutic use (666) 666
antineoplastic agents - therapeutic use (591) 591
thalidomide - administration & dosage (590) 590
aged, 80 and over (581) 581
cancer (576) 576
lenalidomide plus dexamethasone (555) 555
care and treatment (554) 554
chemotherapy (542) 542
transplantation (532) 532
multiple myeloma - therapy (457) 457
prognosis (453) 453
multiple-myeloma (419) 419
multiple myeloma - pathology (399) 399
multiple myeloma - mortality (385) 385
open-label (383) 383
dexamethasone - administration & dosage (381) 381
thalidomide - adverse effects (376) 376
combination (362) 362
hematology, oncology and palliative medicine (342) 342
pharmacology & pharmacy (341) 341
stem cells (335) 335
antineoplastic combined chemotherapy protocols - adverse effects (328) 328
recurrence (324) 324
medicine & public health (322) 322
patients (321) 321
drug therapy (317) 317
pomalidomide (317) 317
disease-free survival (312) 312
analysis (308) 308
myelodysplastic syndromes (296) 296
trial (296) 296
animals (295) 295
elderly-patients (291) 291
myeloma (290) 290
abridged index medicus (283) 283
immunologic factors - therapeutic use (283) 283
research (282) 282
multiple myeloma - diagnosis (279) 279
retrospective studies (275) 275
rituximab (275) 275
melphalan (268) 268
leukemia (261) 261
plus dexamethasone (259) 259
immunology (255) 255
carfilzomib (250) 250
risk factors (248) 248
stem cell transplantation (248) 248
clinical trials (246) 246
low-dose dexamethasone (244) 244
angiogenesis inhibitors (241) 241
efficacy (241) 241
cyclophosphamide (239) 239
diagnosis (229) 229
antineoplastic agents - adverse effects (228) 228
prednisone (226) 226
transplantation, autologous (226) 226
maintenance (225) 225
survival rate (225) 225
thalidomide - pharmacology (222) 222
phase-ii (220) 220
expression (218) 218
survival analysis (215) 215
health aspects (210) 210
immunotherapy (207) 207
hematopoietic stem cell transplantation (204) 204
lymphomas (204) 204
risk (204) 204
hemic and lymphatic diseases (203) 203
clinical trials as topic (201) 201
myelodysplastic syndrome (198) 198
combination therapy (195) 195
medicine, general & internal (195) 195
relapse (192) 192
antineoplastic combined chemotherapy protocols - administration & dosage (189) 189
autologous transplantation (188) 188
myelodysplastic syndromes - drug therapy (187) 187
antineoplastic agents - pharmacology (185) 185
daratumumab (185) 185
follow-up studies (185) 185
bone marrow (184) 184
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4464) 4464
German (71) 71
French (44) 44
Japanese (31) 31
Polish (30) 30
Czech (21) 21
Russian (19) 19
Spanish (19) 19
Chinese (9) 9
Portuguese (6) 6
Korean (4) 4
Hungarian (3) 3
Italian (3) 3
Slovak (3) 3
Turkish (2) 2
Serbian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2019, Volume 37, Issue 7, pp. 589 - 597
Journal Article
Journal of medicinal chemistry, ISSN 0022-2623, 01/2018, Volume 61, Issue 2, pp. 535 - 542
Journal Article
Annals of oncology, ISSN 0923-7534, 2017, Volume 28, Issue 2, pp. 228 - 245
Journal Article
British Journal of Haematology, ISSN 0007-1048, 03/2014, Volume 164, Issue 6, pp. 811 - 821
Summary Cereblon (CRBN), the molecular target of lenalidomide and pomalidomide, is a substrate receptor of the cullin ring E3 ubiquitin ligase complex,... 
lenalidomide | Cereblon | Ikaros | pomalidomide | Aiolos | Pomalidomide | Lenalidomide | Ubiquitin | Genetic transcription | T cells | Ligases | Analysis | Haematological Malignancy
Journal Article
Materials Science and Engineering: C, ISSN 0928-4931, 2019, Volume 98, pp. 419 - 436
In the present investigation, FePt alloy nanoparticles were synthesized with controlled size and elemental composition followed by surface modification using... 
IRON-OXIDE NANOPARTICLES | HYPERTHERMIA | MATERIALS SCIENCE, BIOMATERIALS | CANCER-TREATMENT | PHASE-TRANSFER | SURFACE MODIFICATION | LENALIDOMIDE | MAGNETIC NANOPARTICLES | CYTOTOXICITY | FEPT NANOPARTICLES | DELIVERY | Reactive Oxygen Species - metabolism | Rats, Wistar | Humans | Male | Spectroscopy, Fourier Transform Infrared | Platinum - chemistry | Alloys - chemistry | Endocytosis | Swine | Hyperthermia, Induced | Mucins - metabolism | Cell Survival - drug effects | Photoelectron Spectroscopy | Nanoconjugates - ultrastructure | Iron - chemistry | Hyaluronic Acid - chemistry | Administration, Intranasal | Blood-Brain Barrier - drug effects | Blood-Brain Barrier - metabolism | Phototherapy | Glioblastoma - therapy | Lactoferrin - chemistry | Lenalidomide - administration & dosage | Animals | Lenalidomide - pharmacology | Lenalidomide - therapeutic use | Glioblastoma - pathology | Dogs | Cell Line, Tumor | Drug Liberation | Glioblastoma - drug therapy | Nanoconjugates - chemistry | Oleic Acid - chemistry | Hydrogen-Ion Concentration | Drugs | Drug delivery systems | Brain tumors | Lactoferrins | Alloys | Leaching | Vehicles | Chemotherapy | Analysis | Hyaluronic acid | Magnetic fields | Hydrogen-ion concentration | Cancer | Brain | Intermetallic compounds | Toxicity | Glioblastoma | Cytotoxicity | Cell viability | Mucus | pH effects | Nanoparticles | Lactoferrin | Nanoalloys | Iron compounds | Platinum compounds | Ferrous alloys | Carboxyl group | Extracellular matrix | Biocompatibility | Chemical composition | Hydrazones | I.R. radiation | Intranasal administration | Exposure | Near infrared radiation | Mucin | Acids | Internalization | Irradiation | Infrared lasers | Laser beam heating | In vivo methods and tests | Amino groups
Journal Article
Journal Article
The oncologist (Dayton, Ohio), ISSN 1083-7159, 2010, Volume 15, Issue 1, pp. 6 - 25
Journal Article
BLOOD, ISSN 0006-4971, 09/2019, Volume 134, Issue 13, pp. 1024 - 1036
Journal Article
British journal of haematology, ISSN 0007-1048, 2018, Volume 182, Issue 4, pp. 495 - 503
Summary Smouldering multiple myeloma (SMM) is associated with increased risk of progression to multiple myeloma within 2 years, with no approved treatments.... 
elotuzumab | natural killer cells | multiple myeloma | smouldering multiple myeloma | monoclonal antibody | CS1 | LENALIDOMIDE PLUS DEXAMETHASONE | OPEN-LABEL | THALIDOMIDE | CLINICAL-COURSE | COMBINATION | THERAPY | HEMATOLOGY | PROGRESSION | Antigens, CD - immunology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Neoplasm Proteins - immunology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Antibodies, Monoclonal, Humanized - administration & dosage | Smoldering Multiple Myeloma - immunology | Killer Cells, Natural - immunology | Adult | Female | Antibodies, Monoclonal, Humanized - adverse effects | Dexamethasone - administration & dosage | Smoldering Multiple Myeloma - mortality | Smoldering Multiple Myeloma - blood | Survival Rate | Disease-Free Survival | Lenalidomide - administration & dosage | Antigens, CD - blood | Lenalidomide - adverse effects | Neoplasm Proteins - blood | Aged | Killer Cells, Natural - metabolism | Antibody-Dependent Cell Cytotoxicity - drug effects | Smoldering Multiple Myeloma - drug therapy | Medical research | Fc receptors | Care and treatment | Killer cells | Multiple myeloma | Monoclonal antibodies | Medicine, Experimental | Respiratory tract diseases | Dexamethasone | Toxicity | Cytotoxicity | CD3 antigen | Patients | CD45 antigen | Proteins | Respiratory tract | Infusion | Reduction | CD16 antigen | Smoldering | Bone marrow | Natural killer cells | M protein | Haematological Malignancy | Research Paper
Journal Article
Medicina clínica, ISSN 0025-7753, 04/2014, Volume 142, Issue 8, pp. 360 - 364
Thalidomide is a synthetic glutamic acid derivative first introduced in 1956 in Germany as an over the counter medications. It was thought to be one of the... 
Lenalidomide | Therapeutic | Thalidomide
Journal Article
Haematologica (Roma), ISSN 0390-6078, 06/2020, Volume 105, Issue 6, pp. E276 - E279
Journal Article